During the first of our fortnightly portfolio and market updates focussing on the investment implications of the spread of COVID-19, Jacob Mitchell outlines three unknowns which Antipodes believes will ultimately determine the severity of the developing economic downturn.
To view the full webinar, including comprehensive insights into where Antipodes sees value opportunities in current global markets, click here.
You can register for upcoming webinars in the series here.
Episode 1 Part 1 – Transcript:
What are the sort of unknowns, in terms of the treatment and flattening the infection curve as we’ve all become experts of COVID-19?
There’s potentially positives and negatives out there and it’s really hard to know at this stage because treatments like hydroxychloroquine and azithromycin – we’re not sure of the effectiveness of some of these treatments. In the case of hydroxychloroquine, it’s an antimalarial, there has been some preliminary tests which seem to indicate that it cuts the length of the hospital stay and obviously in terms of taking pressure off of healthcare and hospital facilities that would be a bit of a game-changer.
Secondly, correlation to colder climates: 80% of infections today are really found in parts of the world that were averaging temperatures below 10 degrees Celsius through November, December and into January. Now, once again maybe that is simply the fact that that’s where infections started and a lot of the warmer parts of the world, where we have significant population, in terms of continents – Africa, countries – India, we haven’t done a lot of testing. So there may be a bias in that sample. But if there is a correlation to colder climates, as the northern hemisphere starts to warm up, some of the pressure on the spread should start to lessen.
Thirdly, we don’t know at this stage to what extent there is an emerging herd immunity. I would expect to see a lot more discussion around testing people who don’t have symptoms to see whether or not they’ve already had an infection and they’ve developed immunity.
So as the information on all three of those starts to emerge, we will get a sense of how long the lockdown on economies needs to be. Clearly the shorter the economic lockdown, the less disruptive and less severe the ultimate recession will be.
View the full webinar
This communication was prepared by Antipodes Partners Limited (ABN 29 602 042 035, AFSL 481 580) (Antipodes). Antipodes believes the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. This communication is for general information only and was prepared for multiple distribution and does not take account of the specific investment objectives of individual recipients and it may not be appropriate in all circumstances. Persons relying on this information should do so in light of their specific investment objectives and financial situations. Any person considering action on the basis of this communication must seek individual advice relevant to their particular circumstances and investment objectives. Subject to any liability which cannot be excluded under the relevant laws, Antipodes disclaim all liability to any person relying on the information contained on this website in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information.
Any opinions or forecasts reflect the judgment and assumptions of Antipodes on the basis of information at the date of publication and may later change without notice. Any projections are estimates only and may not be realised in the future. Information on this website is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained on the website is prohibited without obtaining prior written permission from Antipodes.
Pinnacle Fund Services Limited ABN 29 082 494 362 AFSL 238371 is the product issuer of funds managed by Antipodes. Any potential investor should consider the relevant Product Disclosure Statement available at www.antipodesonespartners.com when deciding whether to acquire, or continue to hold units in a fund. The issuer is not licensed to provide financial product advice. Please consult your financial adviser before making a decision. Past performance is not a reliable indicator of future performance.